A new publication dated September 4, 2026, reports on disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population in British Columbia, Canada. The study, titled "Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canada," appears in the Journal of Neuroimmunology. Glatiramer is referenced in the context of this disease-modifying therapy uptake research. The publication is indexed under PubMed ID 42727373. No findings or outcomes beyond the publication's existence and title are stated in the available event data. The study focuses on patterns of therapy uptake among a pediatric-onset MS population within a specific Canadian province. Readers interested in glatiramer as a treatment option can find further context on the compound overview page.
New Publication on Glatiramer Use in Pediatric MS in British Columbia
See the full glatiramer overview
Source: https://pubmed.ncbi.nlm.nih.gov/42727373/